دورية أكاديمية
أعرض في EDS

p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma.

التفاصيل البيبلوغرافية
العنوان: p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma.
المؤلفون: Wu D; Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.; Department of Basic Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu Province 222000, China., Cheng J; Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China., Sun G; Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China., Wu S; Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China., Li M; Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China., Gao Z; Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China., Zhai S; Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China., Li P; Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China., Su D; Center for Clinical Pathology and Laboratory, Affiliated Hospital of Yifu, Nanjing Medical University, Nanjing, Jiangsu Province 211166, China.; Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China., Wang X; Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.; Center for Clinical Pathology and Laboratory, Affiliated Hospital of Yifu, Nanjing Medical University, Nanjing, Jiangsu Province 211166, China.; Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
المصدر: Oncotarget [Oncotarget] 2016 Jun 14; Vol. 7 (24), pp. 36539-36550.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Albany, N.Y. : Impact Journals
مواضيع طبية MeSH: Gene Expression Regulation, Neoplastic*, Epithelial-Mesenchymal Transition/*genetics , Interleukin-6/*genetics , Ribosomal Protein S6 Kinases, 70-kDa/*genetics, Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/metabolism ; Carcinoma, Squamous Cell/parasitology ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Movement/genetics ; Epithelial-Mesenchymal Transition/drug effects ; Head and Neck Neoplasms/genetics ; Head and Neck Neoplasms/metabolism ; Head and Neck Neoplasms/pathology ; Humans ; Interleukin-6/metabolism ; Interleukin-6/pharmacology ; Mitogen-Activated Protein Kinases/metabolism ; Neoplasm Metastasis ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; RNA Interference ; Ribosomal Protein S6 Kinases, 70-kDa/metabolism ; Signal Transduction/drug effects ; Signal Transduction/genetics ; TOR Serine-Threonine Kinases/metabolism
مستخلص: Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide and a common cause of cancer-related death, with a 5-year survival rate of less than 60%. IL-6 has been suggested to play an important role in cancer metastasis, but its mechanism in HNSCC has not been fully clarified. p70S6K has been reported to induce epithelial-mesenchymal transition (EMT) of ovarian cancer, but its role in HNSCC remains unknown. In this study, we found that p70S6K and IL-6 were upregulated in high-metastatic HNSCC cell lines that underwent EMT when compared to paired low-metastatic cell lines. Overexpression of p70S6K promoted EMT and migration of HNSCC cells, while downregulation of p70S6K attenuated IL-6-induced EMT and cell migration. Furthermore, IL-6-induced p70S6K activation was attenuated by inhibitors of the PI3K/Akt/mTOR, MAPK/ERK, and JAK/STAT3 signaling pathways, suggesting that it located downstream of these pathways. These findings suggest that p70S6K promotes IL-6-induced EMT and metastasis of HNSCC. Targeting p70S6K for HNSCC therapy may benefit patients through the inhibition of tumor growth, as well as metastasis.
Competing Interests: There were no conflicts of interest.
References: Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15535-40. (PMID: 20713723)
Mol Cancer Ther. 2006 Jan;5(1):8-19. (PMID: 16432158)
Immunol Cell Biol. 2000 Aug;78(4):447-51. (PMID: 10947872)
Mol Genet Metab. 2015 Mar;114(3):397-402. (PMID: 25533111)
Endocrinology. 2006 May;147(5):2557-66. (PMID: 16469801)
Anticancer Res. 2005 Jul-Aug;25(4):2761-5. (PMID: 16080523)
Cancer Lett. 2010 Sep 1;295(1):110-23. (PMID: 20236757)
Dig Dis Sci. 2013 Oct;58(10 ):2873-80. (PMID: 23912246)
Nat Rev Cancer. 2012 May 11;12 (6):425-36. (PMID: 22576165)
Cell. 2009 Nov 25;139(5):871-90. (PMID: 19945376)
Cancer Biol Ther. 2012 Sep;13(11):1009-17. (PMID: 22825337)
Int J Cancer. 2002 Jun 1;99(4):538-48. (PMID: 11992543)
Int J Clin Exp Pathol. 2015 May 01;8(5):5175-81. (PMID: 26191214)
J Carcinog Mutagen. 2013 Aug 5;Suppl 7:4. (PMID: 25587491)
Nat Rev Cancer. 2011 Jan;11(1):9-22. (PMID: 21160525)
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73. (PMID: 19116269)
Cancer. 2002 Oct 15;95(8):1663-72. (PMID: 12365014)
Prostate. 2004 Jul 1;60(2):120-9. (PMID: 15162378)
Curr Biol. 2002 Apr 16;12(8):632-9. (PMID: 11967149)
Cancer. 2007 Nov 1;110(9):1911-28. (PMID: 17849470)
Cancer Res. 2011 May 1;71(9):3246-56. (PMID: 21430067)
Clin Exp Metastasis. 2006;23(3-4):209-22. (PMID: 17028921)
BMC Cancer. 2003 Sep 17;3:23. (PMID: 13678425)
Oncol Rep. 2012 Aug;28(2):659-67. (PMID: 22664743)
Cytokine. 2001 Nov 7;16(3):79-86. (PMID: 11741345)
Cancer. 2008 Aug 15;113(4):750-7. (PMID: 18536030)
Int J Cancer. 2008 May 1;122(9):1987-98. (PMID: 18172861)
Cancer Res. 2008 Aug 15;68(16):6524-32. (PMID: 18701475)
Cancer Res. 2005 Aug 1;65(15):6516-20. (PMID: 16061629)
Oncotarget. 2014 Aug 30;5(16):6788-800. (PMID: 25216518)
Int J Cancer. 2015 Oct 15;137(8):1879-89. (PMID: 25857630)
Biochem J. 2012 Jan 1;441(1):1-21. (PMID: 22168436)
Blood. 2011 Sep 15;118(11):3129-36. (PMID: 21757621)
Clin Cancer Res. 2013 Jul 15;19(14 ):3808-19. (PMID: 23640975)
Oncogene. 2006 Nov 9;25(53):7029-40. (PMID: 16715128)
Mol Cancer Res. 2011 Dec;9(12 ):1658-67. (PMID: 21976712)
J Biol Chem. 2009 May 29;284(22):14939-48. (PMID: 19332537)
Oral Oncol. 2010 Jun;46(6):429-32. (PMID: 20381408)
Br J Cancer. 2008 Nov 18;99(10):1684-94. (PMID: 19002186)
Curr Protein Pept Sci. 2011 Feb;12(1):30-42. (PMID: 21190521)
Nat Rev Cancer. 2002 Jun;2(6):442-54. (PMID: 12189386)
فهرسة مساهمة: Keywords: HNSCC; IL-6; epithelial-mesenchymal transition; metastasis; p70S6K
المشرفين على المادة: 0 (Interleukin-6)
EC 2.7.1.1 (MTOR protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
تواريخ الأحداث: Date Created: 20160514 Date Completed: 20171227 Latest Revision: 20211204
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5095019
DOI: 10.18632/oncotarget.9282
PMID: 27174914
قاعدة البيانات: MEDLINE
الوصف
تدمد:1949-2553
DOI:10.18632/oncotarget.9282